Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of “Reduce” from Analysts

Posted by on Oct 7th, 2026

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) has received an average recommendation of “Reduce” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $22.50.

A number of brokerages have recently issued reports on AMPH. Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. Wall Street Zen raised Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Barclays increased their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 18th.

View Our Latest Report on AMPH

Insider Activity

In related news, CFO William Peters sold 8,180 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $22.48, for a total value of $183,886.40. Following the transaction, the chief financial officer owned 172,846 shares in the company, valued at $3,885,578.08. This trade represents a 4.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total value of $239,400.00. Following the completion of the sale, the executive vice president owned 169,203 shares of the company’s stock, valued at approximately $4,050,719.82. The trade was a 5.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 33,479 shares of company stock valued at $763,922 over the last 90 days. 29.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new stake in Amphastar Pharmaceuticals during the 2nd quarter worth $4,689,000. Rice Hall James & Associates LLC boosted its position in shares of Amphastar Pharmaceuticals by 54.6% in the 1st quarter. Rice Hall James & Associates LLC now owns 187,348 shares of the company’s stock worth $3,670,000 after purchasing an additional 66,172 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth $1,580,000. Squarepoint Ops LLC grew its stake in shares of Amphastar Pharmaceuticals by 178.0% during the second quarter. Squarepoint Ops LLC now owns 78,795 shares of the company’s stock worth $1,590,000 after purchasing an additional 50,450 shares during the period. Finally, Bank of America Corp DE increased its holdings in Amphastar Pharmaceuticals by 36.0% in the first quarter. Bank of America Corp DE now owns 174,323 shares of the company’s stock valued at $3,415,000 after purchasing an additional 46,149 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ:AMPH opened at $25.91 on Wednesday. Amphastar Pharmaceuticals has a twelve month low of $16.65 and a twelve month high of $29.52. The firm has a market cap of $1.10 billion, a PE ratio of 15.33, a price-to-earnings-growth ratio of 4.89 and a beta of 0.90. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.40. The business has a fifty day moving average of $22.80 and a 200-day moving average of $20.89.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The business had revenue of $183.90 million for the quarter, compared to the consensus estimate of $179.92 million. On average, equities research analysts predict that Amphastar Pharmaceuticals will post 2.46 EPS for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

(Get Free Report)

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on technically challenging medicines, including generic and proprietary products used in emergency care, respiratory treatment, diabetes management and other therapeutic areas.

Its marketed products include Primatene MIST, an over-the-counter epinephrine inhaler for temporary relief of mild, intermittent asthma symptoms; BAQSIMI, a ready-to-use nasal glucagon product for severe hypoglycemia; glucagon injection; Amphadase, a hyaluronidase product; and enoxaparin, an anticoagulant.

Featured Stories

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.